Role of anti cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis

Augustovski F, Pichon Riviere A, Alcarez A, Bardach A, Colantonio L, Ferrante D, Garcia Marti S, Glujovsky D, Lopez A, Regueiro A
Record ID 32007000434
Authors' objectives:

The objective of the report was to assess the usefulness of Anti-CCP in the diagnosis and prognosis of RA.

Authors' results and conclusions: The reported sensitivity of Anti-CCP in the diagnosis of RA is 60% with a range of published reults from 64% to 96% and its specificity, from 88.9% to 100%. These variations were due to the heterogeneity of each study population and the different cut-off points of antibody titles. The sensitivity and specificity did not differ much among the three commercial names of kits used for Anti-CCP analysis. Anti-CCP have also been evaluated prognostic of RA development. The sensitivity of these antibodies for the detection of future RA ranged between 25%-37% and its specificity was 98%. Anti-CCP has also been used as prognostic indicator of progress in patients with diagnosis of RA. The presence of Anti-CCP is associated with a higher probability of disease radiographic progression.
Authors' recommendations: Anti CCP are the best specific markers for RA. The sensitivity of these antibodies is low, though comparable to that of RF (IgM). Although it may be used as RA screening test, the lower cost, wider experience and inclusion of RF as diagnostic criteria for RA makes it more suitable for suspected RA with negative RF or as prognostic factor of erosive or progressive RA.
Authors' methods: Overview
Project Status: Completed
URL for project:
Year Published: 2007
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Arthritis, Rheumatoid
  • Peptides, Cyclic
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
Contact Email:
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.